Enamine is announcing today the expansion of its Purification and Analytical Units to enable synthesis of 30 000 high quality screening library compounds monthly. Such expansion represents the largest development to date of its library synthesis capabilities.
Collaboration with BioVersys AG aiming at discovery of novel treatments against bacterial infections has been extended for the 4th consecutive year.
Enamine and Exquiron are announcing a multi-year collaboration wherby Exquiron is acquiring a large screening compounds libraries from Enamine.
A collaboration agreement has been signed between Enamine, the Medical Research Council Laboratory of Molecular Biology (MRC LMB), Cambridge, UK, and the Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic (IOCB), Prague, Czech Republic. The new alliance is aimed at discovering novel Rhomboid Protease inhibitors as potential drugs to treat infectious, parasitic, oncological, immune and cardiovascular diseases. Enamine will provide the MRC LMB and IOCB with access to its integrated drug discovery capabilities, including Molecular Modeling, Compound Library, Screening Assays, Hit Finding and Characterization, Hit to Lead Chemistry and ADMET. The three parties will seek to partner the small molecule inhibitors generated with pharmaceutical companies for onward clinical development. The collaboration agreement was negotiated by MRC Technology on behalf of MRC LMB.
Enamine Provides Large Novel Diverse Compound Screening Library To Extend Relationship with BioFocus
Enamine Ltd, a leading provider of screening compounds and chemical building blocks, today announced it has extended its long-standing relationship with BioFocus, with the acquisition by BioFocus of a large new compound screening library. The library will be available to BioFocus HTS collaborators in early 2012.
Following the success since 2012 the collaboration with Sanofi aiming at finding of new valuable hit series in most challenging screening campaigns has been extended.
Axxam acquires a 240 000 carefully selected compounds library from Enamine for drug discovery programs
Axxam S.p.A., a contract research and discovery company, announced today that an entirely new generation screening collection is now available for drug discovery programs: AXXDIV2.0 made up with 240 000 carefully selected small molecules.
3D Diversity Set from Enamine, containg 50 000 drug-like compounds, has been selected by ChanTest for their dicovery services using powerful HTS of Ion Channels, GPCRs and Transporters in partnership with pharma and biotech companies.
Enamine and UkrOrgSynthesis Ltd (UORSY), a leading Ukrainian supplier of chemical building blocks and compounds for high-throughput screening, announced they have signed a collaboration agreement to offer chemical building blocks to the drug discovery industry cooperatively. By combining their catalogues, the companies become the largest global manufacturer and seller of building blocks, with 60 000 products available from stock for immediate delivery and an array of ca. 8 million tangible building blocks deliverable with synthetic success rate of 80%.
Molplex and Enamine announced a new partnership to offer Enamine's screening compounds through the Molplex on-line drug design and assay ready chemical supply services. The agreement is a major step towards eliminating the high start-up costs of drug discovery, bringing sophisticated drug design, compound management and assay ready chemistry to the world's drug discovery scientists on demand. The agreement adds Molplex online drug design systems to the deep experience in organic chemistry and compound management of Enamine to solve the problem of generating viable chemical leads for novel targets.